Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 4

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 82Leukemia, Myeloid, Chronic-Phase 22Leukemia 21Gastrointestinal Stromal Tumors 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Neoplasms 8Blast Crisis 7Neoplasm Metastasis 6Philadelphia Chromosome 4Myeloproliferative Disorders 4Melanoma 4Leukemia, Myeloid 4Bone Marrow Diseases 4Recurrence 3Leukemia, Myeloid, Acute 3Hematologic Diseases 3Bronchiolitis Obliterans Syndrome 3Synovitis, Pigmented Villonodular 2Ovarian Neoplasms 2Neoplasm, Residual 2Leukemia, Myeloid, Accelerated Phase 2Hematologic Neoplasms 2Colorectal Neoplasms 2Substance Withdrawal Syndrome 1Sarcoma 1Retroperitoneal liposarcoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Piebaldism 1Peritoneal Neoplasms 1Neurofibromatoses 1

Interventions

Cytarabine 14fludarabine 13venetoclax 11Imatinib Mesylate 9Cyclophosphamide 8Azacitidine 8fludarabine phosphate 7Busulfan 7Whole-Body Irradiation 6Tacrolimus 6Mycophenolic Acid 6thymoglobulin 4ponatinib 4nilotinib 4Sirolimus 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4asciminib 3aldesleukin 3Melphalan 3Interleukin-2 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Decitabine 3Antilymphocyte Serum 3zosuquidar trihydrochloride 2gilteritinib 2enasidenib 2blinatumomab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Leukemia, Myeloid × nilotinib × Clear all
NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Novartis

Phase 2 Completed
104 enrolled 33 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02627677 2021-11-26

OPTIC-2L

Takeda

Phase 3 Terminated
44 enrolled 22 charts
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00471497 2020-11-18

ENESTnd

Novartis

Phase 3 Completed
846 enrolled 33 charts
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

NCT00519090 2011-11-07

ENEST

Novartis

Phase 3 Terminated
6 enrolled 6 charts
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡